Korro Bio Inc
korrobio.comKorro Bio Inc (NASDAQ: KRRO) is a clinical-stage biopharmaceutical company developing RNA editing therapies that make precise single-base edits to target disease-causing proteins. The company generates no product revenue. Its primary disclosed funding arrangement is a Research Collaboration and License Agreement with Novo Nordisk A/S, signed September 13, 2024, with a first amendment filed November 12, 2025, alongside equity offerings and potential future licensing deals. Korro Bio's lead scientific approach targets TDP-43, an RNA/DNA-binding protein whose aggregation is implicated in more than 90% of ALS cases and approximately 45% of frontotemporal dementia cases, per the FY2025 10-K filed March 12, 2026. The company has no approved products and no committed external source of funds, financing operations through equity offerings, debt, and collaboration agreements. Ram Aiyar serves as President and Chief Executive Officer, with Oliver Dolan as Senior Vice President of Finance and Principal Accounting Officer, as disclosed in the FY2025 10-K.
Products & Services
Korro Bio's pipeline centers on RNA editing therapies that introduce single amino acid changes to target proteins. The lead program targets TARDBP, the gene encoding TDP-43, aiming to produce a non-aggregating TDP-43 protein variant as a potential treatment for ALS and frontotemporal dementia. All programs are in preclinical or early development stages as of the FY2025 10-K.
Revenue Model
Korro Bio has no product revenue as of the FY2025 10-K (filed March 12, 2026). The company finances operations through equity offerings, debt financings, and collaboration and licensing arrangements, including a Research Collaboration and License Agreement with Novo Nordisk A/S executed September 13, 2024.
Customers & Markets
The end markets are patients with ALS and frontotemporal dementia. More than 90% of ALS patients and approximately 45% of FTD patients have TDP-43 aggregations in neurons, per the FY2025 10-K. Less than 10% of ALS cases are familial; TARDBP mutations account for approximately 4% of familial ALS cases. There are no commercial customers disclosed.
Geographic Exposure
Korro Bio is a U.S.-incorporated company subject to FDA regulatory oversight for its drug development activities. The FY2025 10-K references GDPR compliance obligations for the EEA and UK, indicating data handling exposure in those regions, but no commercial geographic revenue mix is disclosed.
Financial Snapshot
Loading...
